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Abstract: Hyperphosphatemia is an inevitable consequence of end stage chronic kidney disease 
and is present in the majority of dialysis patients. Recent observational data has associated 
hyperphosphatemia with increased cardiovascular mortality among dialysis patients. Dietary 
restriction of phosphate and current dialysis prescription practices are not enough to maintain 
serum phosphate levels within the recommended range so that the majority of dialysis patients 
require oral phosphate binders. Unfortunately, conventional phosphate binders are not reliably 
effective and are associated with a range of limitations and side effects. Aluminium-containing 
agents are highly efﬁ  cient but no longer widely used because of well established and proven 
toxicity. Calcium based salts are inexpensive, effective and most widely used but there is now 
concern about their association with hypercalcemia and vascular calciﬁ  cation. Sevelamer hydro-
chloride is associated with fewer adverse effects, but a large pill burden and high cost are limiting 
factors to its wider use. In addition, the efﬁ  cacy of sevelamer as a monotherapy in lowering 
phosphate to target levels in severe hyperphosphatemia remains debatable. Lanthanum carbon-
ate is a promising new non-aluminium, calcium-free phosphate binder. Preclinical and clinical 
studies have demonstrated a good safety proﬁ  le, and it appears well tolerated and effective in 
reducing phosphate levels in dialysis patients. Its identiﬁ  ed adverse events are apparently mild 
to moderate in severity and mostly GI related. It appears to be effective as a monotherapy, with 
a reduced pill burden, but like sevelamer, it is signiﬁ  cantly more expensive than calcium-based 
binders. Data on its safety proﬁ  le over 6 years of treatment are now available.
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Introduction
Hyperphosphatemia is an almost inevitable consequence of chronic kidney disease 
(CKD). It occurs in the majority of dialysis patients and continues to represent a major 
challenge to clinical nephrologists. Indeed more than 36% of UK haemodialysis patients 
have plasma phosphate of  1.8 mmol/L (5.5 mg/dL) despite dietary manipulation 
and prescription of oral phosphate binders (Lamb et al 2007).
Normal kidneys ﬁ  lter large amounts of organic phosphate of which more than 
90% is reabsorbed by the renal tubules. Early renal dysfunction reduces ﬁ  ltered 
phosphate but also decreases tubular reabsorption, so that the urinary phosphate 
excretion continues to match gastrointestinal (GI) absorption. Consequently, the net 
balance between phosphate input and output is maintained for a period of time with 
only little change in serum phosphate levels. However, as renal function deteriorates 
further, this homeostatic mechanism fails resulting in positive phosphate balance and 
progressive hyperphosphatemia.
Untreated hyperphosphatemia can lead to secondary hyperparathyroidism 
(SHPT), renal osteodystrophy, vascular calcification and increased morbidity 
and mortality (Lowrie and New 1990; Delmez and Slatopolsky 1992; Block et al 
2004). Retrospective cross-sectional studies suggest that a serum phosphate greater Therapeutics and Clinical Risk Management 2008:4(5) 888
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than 6.5 mg/dL (2.10 mmol/L) is associated with a 27% 
higher mortality risk (relative risk [RR] + 1.27) compared 
with patients with a phosphate level of   2.4–6.5 mg/dL 
(0.78–2.10 mmol/L), and relative risk increases as serum 
phosphate rises (Block and Port 2000). Block et al found that 
a calcium × phosphate product above 72 mg2/dL2 was also 
associated with a signiﬁ  cantly higher relative risk of death 
(RR + 1.34), but this is not surprising if the majority of the 
risk is attributed to the phosphate. Consequently, phosphate 
control remains an important therapeutic target in manage-
ment of CKD, not only to halt progression to secondary 
hyperparathyroidism but also to reduce the risk of vascular 
calciﬁ  cation and cardiovascular mortality, although no pro-
spective interventional studies currently exist to demonstrate 
that this is achievable.
Unfortunately phosphate control has not been signiﬁ  -
cantly improved over the past two decades. Several factors 
may have contributed to this, including the difﬁ  culty of 
adhering to renal diets, phosphate binder prescriptions and 
inadequate phosphate clearance by dialysis. In addition, 
factors such as cost, tolerability, palatability, safety, and 
efﬁ  cacy are also important (Table 1).
We review current management of hyperphosphatemia 
with a particular focus on the pharmacology, clinical efﬁ  cacy, 
and safety proﬁ  le of lanthanum for treatment of elevated 
serum phosphate in dialysis patients.
Management of hyperphosphatemia 
in chronic kidney disease
The standard approach to management of elevated serum 
phosphate in CKD includes dietary restriction, dialysis and 
drug treatment using oral phosphate binders. Unfortunately, 
there are many limitations to this approach which may 
explain the current inability to adequately treat hyperphos-
phatemia.
Firstly, dietary phosphate restriction is impractical for 
many patients who mostly eat pre-prepared, supermarket 
meals rather than freshly prepared foods as in the relatively 
recent past. In addition it can only be restricted to a certain 
extent without risking protein malnutrition, particularly in 
elderly patients (Kopple and Coburn 1973).
Secondly, conventional thrice-weekly, 4-hour hemo-
dialysis removes approximately 1000 mg of phosphate 
each treatment, but this is generally insufﬁ  cient to maintain 
phosphate levels within the recommended targets even if oral 
phosphate intake is signiﬁ  cantly restricted. Peritoneal dialysis 
is little better in this respect (Delmez et al 1982). Kinetic 
studies of hemodialysis have shown that since phosphate 
is predominantly intracellular, serum levels drop rapidly 
in the ﬁ  rst 1–2 hours of dialysis and then reach a plateau. 
They then rise relatively quickly in the ﬁ  rst few hours after 
termination of dialysis, the so-called ‘rebound phenomenon’. 
Although short daily and slow nocturnal haemodialysis may 
be effective in reducing serum phosphate levels, logistic, 
cost and patient acceptance issues limit widespread usage of 
such modalities (Lowrie and Lew 1990). Thus around 90% 
of dialysis patients continue to need additional therapeutic 
maneuvres to improve their phosphate levels.
Traditionally available oral phosphate binding agents, 
though effective in lowering serum phosphate levels are 
not ideal and most have limitations of one sort or another 
(Table 2). Aluminium-based phosphate binders are highly 
efﬁ  cient but have been associated with cognitive disturbances, 
osteomalacia, and anemia which restrict use (Wills and 
Savory 1983; Gonzalez-Revalderia et al 2000). No safe dose 
of aluminium has been identiﬁ  ed and dialysis patients who 
take it even in modest doses have been reported to develop 
clinical evidence of toxicity (Malluche 2002). Nonetheless 
aluminium salts are still used as short term ‘salvage’ therapy 
to achieve acute control of high phosphate levels, and are 
also used in patients whose prognosis is felt to be so short, 
because of other co-morbidities, that the advantages may 
outweigh the risks.
Calcium-based binders (acetate and carbonate) are 
effective and inexpensive but their prolonged administration 
can result in hypercalcemia in over 50% of patients, 
especially when administered with vitamin D analogues 
(Schaefer et al 1992). In addition they can result in over-
suppression of parathyroid hormone (PTH), adynamic bone, 
and are associated with both soft tissue and vascular calci-
ﬁ  cation (Goodman et al 2000; Goodman 2001). However, 
it is worth remembering that vascular calciﬁ  cation was ﬁ  rst 
seen in the 1980s when aluminium hydroxide was the only 
commonly available phosphate binder. Several investigators 
have found calcium acetate to be more effective in binding 
intestinal phosphate, per mmol of administered elemental 
calcium, than calcium carbonate (Mai et al 1989). However, 
Table 1 Suggested characteristics of an ideal oral phosphate binder
High afﬁ  nity for binding phosphate – low dose (pill burden) required
Rapid phosphate binding regardless of ambient pH
Low solubility
Low systemic absorption (preferably none)
Non toxic and without side effects
Solid oral dose form
Palatable – encourages compliance
InexpensiveTherapeutics and Clinical Risk Management 2008:4(5) 889
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Table 2 Comparison of currently available oral phosphate binders
Phosphate binder Advantages Disadvantages
Calcium carbonate Aluminium free Efﬁ  cacy inﬂ  uenced by pH
Moderately effective Unpalatable
Moderate pill burden Hypercalcemia
Cheap GI side effects
Possible ectopic calciﬁ  cation
Calcium acetate Aluminium free Large tablets need to be swallowed
Efﬁ  cacy some what pH dependent Hypercalcemia
Moderately cheap GI side effects
Lower calcium load than carbonate Possible ectopic calciﬁ  cation
Calcium free
Aluminium salts High efﬁ  cacy regardless of pH Aluminium toxicity
Cheap No deﬁ  nite safe dose
Not pH dependent Frequent monitoring needed
Magnesium salts Moderate pill burden GI side effects
Calcium and aluminium free Not widely used
Moderate efﬁ  cacy Magnesium monitoring
Moderate pill burden
Sevelamer Calcium and aluminium free Expensive
No GI tract absorption Efﬁ  cacy inﬂ  uenced by pH
Moderate efﬁ  cacy High pill burden
Reduces total and LDL cholesterol GI side effects
Binds fat-soluble vitamins
Lanthanum carbonate  Calcium and aluminium free Expensive 
Chewed, not swallowed whole GI side effects 
High efﬁ  cacy regardless of pH Minimal GI absorption
Low pill burden
Abbreviations:  GI, gastrointestinal; LDL cholesterol, low density lipoprotein cholesterol.
compliance and patient tolerability are generally poor with 
calcium acetate and the studies showing a greater reduction 
in mean serum phosphate level, compared with the same dose 
of calcium carbonate, were relatively short-term (Qunibi 
et al 2004).
Magnesium-containing phosphate binders can be used 
as an alternative to calcium-based agents but generally they 
are less effective, and are associated with increased serum 
magnesium levels and diarrhea. However, magnesium iron 
hydroxycarbonate is a new oral phosphate binder currently 
undergoing clinical trials, with promising results presented 
in abstract form only so far (McIntyre 2007).
Sevelamer hydrochloride was the ﬁ  rst synthetic non-
aluminium and calcium-free phosphate binder to become 
available. It was originally developed to lower plasma 
lipids and has this beneﬁ  cial side effect in CKD patients. In 
several open label studies sevelamer appears as effective as 
calcium-based binders in lowering phosphate, but without 
the tendency to promote hypercalcemia (Bleyer et al 1999). 
Furthermore, there is some evidence that sevelamer hydro-
chloride can attenuate coronary and aortic calciﬁ  cation com-
pared with calcium-based phosphate binders (Chertow et al 
2002). Despite these advantages, GI disturbances, metabolic 
acidosis, and cost are limiting factors affecting the wider use 
of sevelamer hydrochloride. Unfortunately the large pill bur-
den required to achieve target phosphate levels can adversely 
affect patient adherence. Nonetheless, sevelamer remains an 
important current therapy in the management of hyperphos-
phatemia. More recently lanthanum carbonate became widely 
available in the US (January 2005) and EU (July 2006), and 
is also a nonaluminium-, noncalcium-based binder.
Pharmacology
Lanthanum is a naturally occurring rare-earth element with 
a molecular weight of 139 Da and atomic number 57. The 
element was discovered by Carl Gustaf Mosander in 1839. Therapeutics and Clinical Risk Management 2008:4(5) 890
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It is particularly abundant in China where it is mined, but 
can be found in many green leafy vegetables and also in tap 
water in the UK. As a phosphate binder, lanthanum is ingested 
as the carbonate salt, and it dissociates in the upper GI tract 
to the lanthanum ion (La3+). It binds phosphate ionically, 
optimally at pH 3–5, while retaining its phosphate-binding 
capacity across the full pH range from 1 to 7 (Hutchison and 
Al-Baaj 2005). Unlike calcium-based binders and sevelamer 
hydrochloride, lanthanum has been shown in vitro to bind 
phosphate efﬁ  ciently even at the low pH found in the stomach, 
as well as the high pH values found in the duodenum and 
jejunum. This range of pH for binding phosphate is similar 
to that seen with aluminium salts (3–5).
Animal studies have shown that lanthanum has similar 
phosphate binding efﬁ  cacy to aluminium, but dramatically 
lower oral bioavailability. In a nephrectomized rat model it 
reduced urinary phosphate levels to the same extent as alumin-
ium, and more effectively than calcium carbonate or sevelamer 
(Finn et al 2004). Lanthanum has a low potential for accumu-
lation with only 0.00005% of the oral dose being absorbed 
via the canine GI tract (Shire Pharmaceuticals Group, data on 
ﬁ  le) compared with 0.05%–0.1% for aluminium (Knoll et al 
1984). The small absorbed fraction is eliminated primarily by 
the liver, not the kidneys, with 85% of this being eliminated 
in bile and 13% directly across the gut wall (Hutchison 2004; 
Damment and Pennick 2007). In rats 99.3% of an oral dose 
is excreted in faeces with only 0.004% excreted in urine 
(Hutchison 2004). In man the absolute bioavailability of lan-
thanum (administered as lanthanum carbonate) was extremely 
low (0.00127% ± 0.00080%), with individual values in the 
range of 0.00015%–0.00224% (Pennick et al 2006). Renal 
clearance was negligible after oral administration (1.36 ± 
1.43 mL/min), and intravenous administration conﬁ  rmed 
this low renal clearance (0.95  ±  0.60 mL/min) – just 1.7% 
of total plasma clearance. Furthermore, in contrast to alu-
minium, lanthanum does not cross the blood brain barrier, 
so that the potential for neurological adverse side effects is 
extremely low (Damment et al 2007). Lanthanum carbonate 
is not known to induce any systemic drug reactions and has 
no effect on cytochrome P450 enzymes.
Clinical efﬁ  cacy
The results of published data on lanthanum carbonate 
demonstrate that lanthanum has many of the characteristics 
of an effective phosphate binder. Pre-clinical animal studies 
suggested that lanthanum may be similar to aluminium 
in phosphate lowering capacity but with a much more 
favourable safety proﬁ  le.
Phase II studies revealed a statistically significant 
decrease in phosphate levels in patients receiving lanthanum 
carbonate at a dose of 1500–3000 mg/day in two double blind 
placebo controlled studies (Hutchison et al 2004; Al-Baaj 
et al 2005). The maximal decrease in serum phosphate levels 
occurred after 3 weeks of treatment and was maintained over 
the 3–6 weeks of treatment.
Three large multicenter phase III studies were performed 
to evaluate the efﬁ  cacy and safety of lanthanum carbonate. 
The ﬁ  rst trial was a 13-week randomized, double-blind, 
placebo-controlled, parallel-group study which showed a 
highly signiﬁ  cant difference in the mean serum phosphate 
levels between lanthanum and placebo groups (Joy and 
Finn 2003). Serum phosphate levels were controlled at 
1.9 mmol/L in 59% of patients receiving lanthanum vs 
23% in the placebo group. Moreover, 66% of the lanthanum-
treated group maintained a controlled phosphate level at 
study end point, compared with 31% of the placebo group. 
Ca × P product (52.37 ± 14.89 vs 66.59 ± 18.30 mg/dL; 
p  0.0001), and serum PTH levels (209.41 ± 152.65 vs 
291.80 = 194.82 pg/mL; p  0.01) were signiﬁ  cantly lower 
with lanthanum carbonate treatment than with placebo.
In a second large prospective, randomized, European, 
multi-center, open label comparator trial, the efﬁ  cacy of 
lanthanum carbonate was compared with calcium carbonate 
(Hutchison et al 2005). In total around 800 patients were 
randomized (533 to lanthanum and 267 to calcium car-
bonate). After 1–3 weeks of ‘washout’ from any previous 
binder therapy, patients with hyperphosphatemia (serum 
phosphate 1.8 mmol/L (5.58 mg/dL)) were randomized 
to 5 weeks of dose titration with either lanthanum carbonate 
(375–3000 mg/day) or calcium carbonate (1500–9000 mg/
day) followed by a 20-week maintenance period. The pri-
mary end point was reduction of serum phosphate levels 
to 1.8 mmol/L. The secondary efﬁ  cacy parameter was 
maintenance of phosphate control at 1.8 mmol/L for 6 
months or longer. PTH, calcium, and calcium × phosphate 
product levels were also monitored throughout the study.
After 9 weeks of treatment both groups had serum phos-
phate levels of around 1.69 mmol/L (Figure 1). The propor-
tion of patients achieving controlled phosphate levels of 
1.8 mmol/L was similar in both treated groups (lanthanum 
65.8%, calcium 63.9%) at the end of maintenance phase 
(p = NS). The reduction in calcium × phosphate product was 
generally greater in the lanthanum carbonate group at the end of 
the maintenance phase  −1.59 vs  −1.2 mmol/L). Perhaps most 
importantly from a clinical perspective, there was a signiﬁ  cantly 
higher incidence of hypercalcemia in the calcium-treated group Therapeutics and Clinical Risk Management 2008:4(5) 891
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(20.2%) than in the lanthanum group (0.4%), as one would 
expect with a noncalcium-based binder.
A similar but longer-term study was performed in the US, 
in which lanthanum monotherapy was compared with any 
other standard phosphate binder or combination of binders 
(Finn 2006). After washout, patients were randomized to 
receive lanthanum carbonate (n = 682) or their pre-study 
phosphate binder (n = 677). Over a 6-week period, lanthanum 
carbonate was titrated to a maximum daily dose of 3000 mg 
elemental lanthanum (serum phosphate target levels for 
titration were 1.90 mmol/L). Over 2 years of follow up, 
phosphate control was similar in both groups but in the lantha-
num group serum calcium was lower and serum PTH levels 
were maintained in the range recommended by K/DOQI. 
The most common adverse events were gastrointestinal. The 
incidences of events in the lanthanum and standard therapy 
groups were nausea, 37% vs 29%; vomiting, 27% vs 22%, 
and diarrhea (24% in each group). There was no indication 
of  liver toxicity, suppression of erythropoiesis, or changes in 
the mini-mental state examination, and the authors concluded 
that the 2-year tolerability and efﬁ  cacy of lanthanum were 
similar to those seen with any other standard therapy.
Subsequently the effect of lanthanum carbonate 
compared with calcium carbonate on development of renal 
osteodystrophy was evaluated in an open label bone biopsy 
study among patients undergoing dialysis (D’Haese et al 
2003). At base line 98% of patients in each group had 
evidence of renal osteodystrophy in their bone biopsy. 
Ninety-eight patients were randomized to receive lanthanum 
or calcium carbonate at a dose of 3750 or 9000 mg/day 
respectively for 1 year, followed by a repeat bone biopsy. 
After 1 year of treatment, 63 paired bone biopsy samples 
were analyzable. A greater proportion of patients with low 
bone turnover lesions (adynamic bone or osteomalacia) at 
their baseline biopsy approached normalization on lanthanum 
treatment, compared to those given calcium (71% vs 43% 
respectively). At the end of the study 30% (n = 9) of calcium-
treated patients had adynamic bone histology, compared with 
only 9% (n = 3) of the lanthanum-treated group. Moreover, 
no evidence of any adverse effect on osteoblast function 
could be seen, and there was no correlation between bone 
lanthanum content and parathyroid hormone levels.
Safety data
Preclinical animal studies of lanthanum have shown no 
adverse effects at doses up to 2000 mg/kg body weight, 
suggesting a large safety margin for this compound. More 
importantly clinical studies have shown no evidence of 
toxicity affecting liver, bone or brain.
In common with all oral phosphate binders, lanthanum 
carbonate causes some GI side effects in around 20% 
of patients, but these seem to be relatively minor in 
most (abdominal pain, nausea, vomiting, diarrhea, and 
constipation). Avoidance of hypercalcemia is the major 
beneﬁ  t of any noncalcium-based binder, and this may prove 
to be lanthanum’s biggest safety beneﬁ  t.
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Figure 1 Mean serum phosphate levels during titration and maintenance treatment in the ITT population.Therapeutics and Clinical Risk Management 2008:4(5) 892
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Long-term safety of lanthanum has been examined in a 
number of open-label extension studies with exposure over 6 
months (Hutchison et al 2005), 2 years (Finn 2006), 3 years 
(Hutchison et al 2006), and most recently 6 years (Hutchison 
et al 2008). In all these studies no evidence of toxicity has 
been seen, and in particular no adverse effects related to liver, 
bone, or brain, which have been often raised as possible target 
organs despite the paucity of supporting data.
In the large phase III prospective study of 197 patients 
randomized to receive either lanthanum carbonate or any 
other ‘standard’ phosphate binders, bone biopsies were 
obtained at baseline and again after either 1 or 2 years of 
treatment. No adverse effects on bone histology were seen in 
the lanthanum group. In another study 11 patients selected at 
random who had been in an open-label extension study and 
taking lanthanum carbonate for more than 4 years showed no 
evidence of low turnover or aluminium-like effects in their 
bone biopsies. Clinical studies with up to 6 years follow up 
have demonstrated no hepatotoxic effects related to treatment 
in terms of liver enzyme changes.
The place of lanthanum 
in treatment of hyperphosphatemia
On the basis of its proven efﬁ  cacy and safety proﬁ  les, it is 
justiﬁ  able to consider lanthanum carbonate as a ﬁ  rst-line 
phosphate binder for dialysis patients. However, such 
decisions are rarely made on solely clinical grounds, and 
while it is clearly effective without evidence of toxicity, 
it is also expensive, with three 500 mg lanthanum tablets 
costing approximately the same as ﬁ  ve 800 mg sevelamer 
pills. However, once the sevelamer prescription increases 
beyond this number of pills, the dose of lanthanum 
becomes cheaper at UK prices. Furthermore the dose 
of lanthanum can be increased without increasing the 
number of tablets, since it is manufactured in different 
strengths – 500, 750, and 1000 mg – making it unique 
among phosphate binders.
Lanthanum carbonate and sevelamer are both signiﬁ  -
cantly more expensive than calcium-based binders. In the 
light of current ﬁ  nancial constraints and the rising cost of 
medical care, a cost/beneﬁ  t pharmaco-economic study com-
paring lanthanum carbonate with other phosphate binders 
is warranted but is virtually impossible without conducting 
prospective outcome studies.
The reduced pill burden combined with palatability and 
tolerability may lead to improvement in patient adherence 
to therapy, and therefore better phosphate control, although 
adherence is not solely related to pill burden. Phosphate 
can be controlled in most patients with a dose between 
1500 and 3000 mg daily, so that the prospect of  2–3 tablets 
daily is real.
In a multicenter, open-label trial, patients on a stable dial-
ysis regimen were screened while receiving phosphate-binder 
therapy, then entered into a washout phase (Hutchison and 
Laville 2008). Patients with serum phosphate 1.78 mmol/L 
after washout entered into the main 12-week treatment phase 
(N = 367), during which they were treated to target (K/DOQI: 
1.13–1.78 mmol/L) with lanthanum carbonate monotherapy. 
Mean serum phosphate levels were signiﬁ  cantly reduced after 
12 weeks of lanthanum carbonate monotherapy vs previous 
phosphate-binder therapy. The mean number of phosphate-
binder tablets being taken per day at screening was 7.6, but 
during treatment with lanthanum carbonate, most patients 
were taking doses of up to 3000 mg/day, achievable with 
3 × 1000 mg tablets per day. These ﬁ  ndings suggest that 
lanthanum carbonate monotherapy offers effective control 
of serum phosphate and, owing to a low tablet burden, may 
help to simplify the management of hyperphosphatemia in 
patients with CKD Stage 5.
Conclusion
Hyperphosphatemia is prevalent in the dialysis population 
and is considered by many to be an independent risk factor 
associated with cardiovascular morbidity and mortality. Its 
control remains a challenging issue for clinical nephrologists 
because none of the traditional therapeutic approaches appear 
entirely satisfactory. Dietary restrictions are difﬁ  cult to fol-
low and standard hemodialysis is inadequate for removal 
of phosphate, so that the vast majority of dialysis patients 
require oral phosphate binders. Until recently none of the 
available agents fulﬁ  lled the criteria of an ideal phosphate 
binder. The introduction of sevelamer hydrochloride and 
subsequently lanthanum carbonate represents a signiﬁ  cant   
development in phosphate management. Both are nonalu-
minium, calcium-free agents. Sevelamer achieves effective 
phosphate lowering and may attenuate progression of 
vascular calciﬁ  cation in hamodialysis patients. However, 
its large pill burden and high cost are major disadvantages 
which have adversely affected treatment compliance and the 
wider use of sevelamer.
Lanthanum carbonate represents another step on the way 
to complete phosphate control. Evidence suggests that it is an 
effective, well tolerated and safe phosphate binder. Lantha-
num does not cause hypercalcemia, is effective in reducing 
calcium × phosphate product, and may have a positive effect 
on bone histology.Therapeutics and Clinical Risk Management 2008:4(5) 893
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